RIFAXIMIN
Strength550 mg
Formoral.solid
550 mg 3 times daily (or 400 mg 3 times daily) x 14 days
Specialist pediatric gastroenterology use only
ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth 2020
Non-absorbable gastrointestinal-targeted antibiotic with minimal systemic side effects
- Rifaximin is the first-line treatment for hydrogen-predominant SIBO per ACG 2020.
- Address underlying motility or structural cause to prevent high recurrence rate.
- Rifaximin is a non-absorbable antibiotic (<0.4% systemic absorption).
| Egyptian brand | Manufacturer | Indicative price |
|---|---|---|
| IDIBACT 550 MG 20 F.C.TAB. | INTERNATIONAL DRUG INDUSTRIES > NOVELL PHARMA | 103.75 EGP (5.19/unit) |
| ROLAXIMINE 550 MG 30 F.C. TAB. | EVA PHARMA > HORUS FOR PHARMACEUTICAL PRODUCTS | 225.00 EGP (7.50/unit) |
| RIFAXEROSE 550 MG 10 F.C. TABS. | AVERROES PHARMA | 82.00 EGP (8.20/unit) |
| BIOREFAMIN 550 MG 10 F.C.TABS. | P & C LABS > SOVALUE PHARMA | 148.00 EGP (14.80/unit) |
| DUFAXIMIN 550 MG 28 F.C. TABS. | AUG PHARMA | 480.00 EGP (17.14/unit) |
| FATROXIM 550 MG 30 F.C. TAB. | EGPI > ATM PHARMACEUTICAL INDUSTRIES | 516.00 EGP (17.20/unit) |
| GASTROBIOTIC 550 MG 30 F.C. TAB. | ANDALOUS PHARMA | 516.00 EGP (17.20/unit) |
| TRAVIGUARD 550 MG 20 F.C. TABS. | P AND C LABS > TREND PHARM | 344.00 EGP (17.20/unit) |